Text Size:AAA

BAFF/BLyS/TNFSF13B  Protein, Antibody, ELISA Kit, cDNA Clone

製品の説明: Active  
発現宿主: Human Cells  
  • Slide 1
10056-H01H-5
10056-H01H-20
10056-H01H-100
5 µg 
20 µg 
100 µg 
Add to Cart
発現宿主: E. coli  
  • Slide 1
10056-HNAE-50
10056-HNAE-20
50 µg 
20 µg 
Add to Cart
製品の説明: Active  
発現宿主: Human Cells  
  • Slide 1
10056-HNCH-500
10056-HNCH-5
10056-HNCH-20
10056-HNCH-100
10056-HNCH-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
90267-C01H-50
90267-C01H-20
90267-C01H-100
50 µg 
20 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
70112-D01H-50
70112-D01H-20
50 µg 
20 µg 
Add to Cart

BAFF/BLyS/TNFSF13B Related Area

BAFF/BLyS/TNFSF13B 関連経路

BAFF/BLyS/TNFSF13B 関連製品

BAFF/BLyS/TNFSF13B 関連製品

Featured Reagent Products

BAFF/BLyS/TNFSF13B サマリー & タンパク質情報

BAFF/BLyS/TNFSF13B 関連情報

BAFF/BLyS/TNFSF13B 背景

遺伝子の概要: The protein encoded by TNFSF13B gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011]
General information above from NCBI
サブユニット構造: Homotrimer. Isoform 2 heteromultimerizes with isoform 1, probably limiting the amount of functional isoform 1 on the cell surface. Isoform 3 is unlikely form trimers or bind to BAFF receptors. {ECO:0000269|PubMed:12867412, ECO:0000269|PubMed:22749832}.
細胞内位置: Cell membrane; Single-pass type II membrane protein.; Tumor necrosis factor ligand superfamily member 13b, soluble form: Secreted.
組織特異性: Abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. Also found in the spleen, lymph node, bone marrow, T-cells and dendritic cells. A lower expression seen in placenta, heart, lung, fetal liver, thymus, and pancreas. Isoform 2 is expressed in many myeloid cell lines. {ECO:0000269|PubMed:12867412}.
誘導: Up-regulated by exposure to IFNG/IFN-gamma. Down-regulated by phorbol myristate acetate/ionomycin treatment.
翻訳後: The soluble form derives from the membrane form by proteolytic processing.; Isoform 2 is not efficiently shed from the membrane unlike isoform 1. {ECO:0000250}.; N-glycosylated.
シーケンスの類似性: Belongs to the tumor necrosis factor family. {ECO:0000305}.
General information above from UniProt

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

BAFF/BLyS/TNFSF13B 代替名

BAFF/BLyS/TNFSF13B 関連研究

  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"